Can Antisense Trump Oral?
'In a Year, We'll Know': Isis' Kynamro Faces Juxtapid Pill
By Randy Osborne
Wednesday, January 30, 2013
Timing of the launch, how to identify new patients and the retry for approval in Europe along with, of course, price became topics of talk in the aftermath of Kynamro's approval Tuesday by the FDA for homozygous familial hypercholesterolemia (HoFH).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.